Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds

US8486398B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Joanne Van Ryn · Warthausen, DE
• John Park · Warthausen, DE
• Norbert Hauel · Schemmerhofen, DE
• Ulrich Kunz · Ingelheim am Rhein, DE
• Tobias Litzenburger · Mittelbiberach, DE
• Keith Canada · Southbury, US
• Sanjaya Singh · Sandy Hook, US
• Alisa K. Waterman · Weston, US

Key dates

• Filing date: Jan 20, 2011
• Grant date: Jul 16, 2013
• Expiry date: Feb 27, 2031

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.